Saturday, 27 July 2013

Family cancer-history increases risk of multiple types

Research suggests that having cancer in the family can increase a person's chances of developing not only the same type of cancer, but others too. A study of 23,000 people in Italy and Switzerland concluded that for each of 13 cancer types, close relatives had an increased risk of the same disease. However there was also evidence that a family history of one cancer could significantly raise the risk of others.

The research, published in the journal Annals of Oncology, followed 12,000 patients with cancer at different sites in the body, who were compared with 11,000 people without cancer. The researchers collected information on family history of cancer, particularly in a first-degree relative (those who share about 50% of their genes such as a parent, sibling or child).

They discovered that people with a first-degree relative with cancer of the larynx had triple the normal risk of developing oral and pharyngeal cancer. Those closely related to someone with oral and pharyngeal cancer had a fourfold increased risk oesophageal cancer, while breast cancer doubled the risk of ovarian cancer for female family members. In addition to this men had a 3.4-fold increase in prostate cancer if a first-degree relative had bladder cancer. The research also confirmed some known cancer risks; they include a raised risk of women developing breast cancer if they have a family history of bowel cancer.

Study leader Dr Eva Negri, of the Mario Negri Institute for Pharmacological Research in Milan, Italy, said: "What this study has highlighted is that sometimes if you have a relative with one cancer your risk of another cancer can be increased. The relative risk of a different cancer generally tends to be lower than for the same cancer." She added that in some cases, the links between different cancers may be due to shared environmental factors, such as family smoking and drinking habits. However there was also evidence of genetic factors that affected multiple cancer sites in the body.

Jessica Harris, the senior health information manager at Cancer Research UK, explained that cancer risk is determined by a combination of genes we inherit from our parents, our lifestyles, and our environment. She said: "Whether or not someone in your family has had cancer, living a healthy life can really help to stack the odds in our favour, and reduce the risk of cancer. The main things you can do are to be a non-smoker, cut down on alcohol, and stay in shape by being active and eating a balanced diet."

Jack

Friday, 19 July 2013

Pioneering stem cell trial approved

The first trial of stem cells produced from a patient's own body has been approved by the Japanese government - Japan's health minister, Norihisa Tamura, ruled that the cells can now be tested in patients. Researchers in Japan will use the cells to attempt to treat a form of blindness - age-related macular degeneration. The announcement was described as a "major step forward" for research in this field.

There are already clinical trials taking place that use stem cells harvested from embryos, but this is ethically controversial and the cells will not match a patient's own tissues, so there is a risk of rejection. Induced pluripotent stem cells (IPSCs), however, are made by coaxing a sample of the patient's skin to become stem cells, so there should be no risk of rejection.

The trial will be run by the Riken Center for Developmental Biology and the Institute of Biomedical Research and Innovation Hospital in Kobe. Initially, six patients will receive transplants of cells to see if the procedure can restore their damaged vision.

Prof Chris Mason, an expert on regenerative medicine at University College London said: "This was expected, but it's obviously a major step forward. They [IPSCs] are beneficial for two main reasons. One, they are from the patients themselves so the chance of rejection is greatly reduced and there are the ethical considerations - they do not have the baggage which comes with embryonic stem cells." However the downside to IPSCs is that they were discovered much later than embryonic stem cells, so the science is not as advanced and therefore the technology is less safe.

Jack

Friday, 12 July 2013

Gene therapy trial 'cures children'

A disease that robs children of the ability to walk and talk has been cured by pioneering gene therapy to correct errors in their DNA, say doctors in a study published in Science. A second study published at the same time has shown a similar therapy reversing a severe genetic disease that affects the immune system. Gene therapy researchers described it as a "really exciting" development.

Babies born with metachromatic leukodystrophy appear healthy, but their development starts to reverse between the ages of one and two as part of their brain is destroyed. Wiskott-Aldrich syndrome leads to a defective immune system; it makes patients more susceptible to infections, cancers, and the immune system can also attack other parts of the body.

The treatment technique, developed by a team of researchers at the San Raffaele Scientific Institute in Milan, Italy, used a genetically modified virus to correct the damaging mutations in a patient's genes. Bone marrow stem cells are taken from the patient and then the virus is used to 'infect' the cells with tiny snippets of DNA which contain the correct coding instructions - these are then put back into the patient. The treatment was carried out on three children from families with a  history of metachromatic leukodystrophy, but before their brain function started to decline.

Dr Alessandra Biffi said: "The outcome has been very positive, they're all in very good condition, with a normal life and going to kindergarten at an age when their siblings were unable to talk." She said that all treatments had side effects and these patients needed to be followed for longer, but the evidence so far suggested the treatment was safe.

In the other study, which was published simultaneously in Science, symptoms such as repeat infections and eczema had lessened in the three patients treated. Prof Luigi Naldini, who leads the San Raffaele Telethon Institute for Gene Therapy, said: "Three years after the start of the clinical trial the results obtained from the first six patients are very encouraging. The therapy is not only safe, but also effective and able to change the clinical history of these severe diseases."

Jack

Friday, 5 July 2013

Stem-cell livers grown in lab

Tiny functioning human livers have been grown from stem cells in a laboratory by scientists in Japan. The scientists said they were "gobsmacked" when liver buds, the earliest stage of the organ's development, formed spontaneously. The team, reporting their findings in Nature, hope that transplanting thousands of liver buds could reverse liver failure.

Scientists around the world are trying to grow organs in the lab in order to overcome the shortage of organ donors. Some patients already have bladders made from their own cells, but dense solid organs such as the liver and kidneys are much harder to produce.

The team at the Yokohama City University were reproducing the earliest stages of liver development, similar to that in an embryo. They had mixed three types of cells - two types of stem cells and material taken from the umbilical cord. Unexpectedly, the cells began to organise themselves and appeared to curl up to form a liver bud. These buds were then transplanted into mice, where they hooked themselves up with the blood supply and began to function as little livers. This resulted in increased lifespans in the mice that had liver failure.

Prof Takanori Takebe said: "We just simply mixed three cell types and found that they unexpectedly self-organise to form a three-dimensional liver bud - this is a rudimentary liver. And finally we proved that liver bud transplantation could offer therapeutic potential against liver failure."

It is thought that other organs such as the pancreas, kidneys and even the lungs could be developed in the same way. However, turning this concept into a treatment is still a distant prospect. The buds are 4-5 mm in length but the researchers say they would need to develop buds that are much smaller and could be injected into the blood. The buds would not grow to be a whole new liver, but would embed themselves in the failing one and restore it.

Dr Varuna Aluvihare, a liver transplant physician at King's College Hospital in London, said:
"This is a great piece of work and as a proof of concept, very interesting. The real highlight is that such simple mixtures of cells can differentiate and organise themselves into highly complex issue structures that function well in an animal model." However he also said that the liver was very damaged in chronic liver disease so there were still questions about where the buds were transplanted and how they would function. The risk of a tumour developing after the transplant would also need to be assessed.

Jack